Current Infectious Disease Reports

, Volume 8, Issue 2, pp 151–161 | Cite as

Vaccination in patients with HIV infection

  • Todd D. Gleeson
  • Mark R. Wallace
  • Sybil A. Tasker


Although vaccine-preventable diseases are common in HIV, concerns about vaccine safety and lack of efficacy in this patient population often lead to missed opportunities for vaccination. In this article, we review the literature regarding vaccine risks and benefits and offer recommendations regarding their use and timing in patients with HIV infection.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Pirofski LA, Casadevall A: Use of licensed vaccines for active immunization of the immunocompromised host. Clin Microbiol Rev 1998, 11:1–26. A definitive review of vaccination in immunosuppressed patients, especially strong on live vaccines. Excellent tables and complete reference list.PubMedGoogle Scholar
  2. 2.
    Rhoads JL, Birx DL, Wright DC, et al.: Safety and immunogenicity of multiple conventional immunizations administered during early HIV infection. J Acquir Immune Defic Syndr 1991, 4:724–731.PubMedGoogle Scholar
  3. 3.
    Janoff EN, Hardy WD, Smith PD, Wahl SM: Humoral recall responses in HIV infection. Levels, specificity, and affinity of antigen-specific IgG. J Immunol 1991, 147:2130–2135.PubMedGoogle Scholar
  4. 4.
    Kroon FP, van Dissel JT, de Jong JC, van Furth R: Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD4+ lymphocytes. AIDS 1994, 8:469–476.PubMedCrossRefGoogle Scholar
  5. 5.
    Kroon FP, van Dissel JT, Labadie J, et al.: Antibody response to diphtheria, tetanus, and poliomyelitis vaccines in relation to the number of CD4+ T lymphocytes in adults infected with human immunoDeficiency virus. Clin Infect Dis 1995, 21:1197–1203.PubMedGoogle Scholar
  6. 6.
    Borkowsky W, Rigaud M, Krasinski K, et al.: Cell-mediated and humoral immune responses in children infected with human immunoDeficiency virus during the first four years of life. J Pediatr 1992, 120:371–375.PubMedCrossRefGoogle Scholar
  7. 7.
    Moore D, Nelson M, Henderson D: Pneumococcal vaccination and HIV infection. Int J STD AIDS 1998, 9:1–7.PubMedGoogle Scholar
  8. 8.
    Janoff EN, Tasker SA, Stevenson M, et al.: Immune activation and virologic response to immunization in recent HIV type 1 seroconverters. AIDS Res Hum Retroviruses 1999, 15:837–845.PubMedCrossRefGoogle Scholar
  9. 9.
    Weiss PJ, Wallace MR, Oldfield EC 3rd, et al.: Response of recent human immunoDeficiency virus seroconverters to the pneumococcal polysaccharide vaccine and Haemophilus influenzae type b conjugate vaccine. J Infect Dis 1995, 171:1217–1222.PubMedGoogle Scholar
  10. 10.
    Kroon FP, Rimmelzwaan GF, Roos MT, et al.: Restored humoral immune response to influenza vaccination in HIV-infected adults treated with highly active antiretroviral therapy. AIDS 1998, 12:F217–223.PubMedCrossRefGoogle Scholar
  11. 11.
    Melvin AJ, Mohan KM: Response to immunization with measles, tetanus, and Haemophilus influenzae type b vaccines in children who have human immunoDeficiency virus type 1 infection and are treated with highly active antiretroviral therapy. Pediatrics 2003, 111:e641–644. This paper is an excellent example of studies demonstrating the benefit of HAART on antibody response to vaccination. Antibody responses were significantly improved after immune reconstitution.PubMedCrossRefGoogle Scholar
  12. 12.
    Lange CG, Lederman MM, Medvik K, et al.: Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection. AIDS 2003, 17:2015–2023. Important study that found nadir CD4+ T-cell count, not CD4 count at time of vaccination, predicted immunization response.PubMedCrossRefGoogle Scholar
  13. 13.
    Armbruster C, Junker W, Vetter N, Jaksch G: Disseminated bacille Calmette-Guerin infection in an AIDS patient 30 years after BCG vaccination. J Infect Dis 1990, 162:1216.PubMedGoogle Scholar
  14. 14.
    Redfield RR, Wright DC, James WD, et al.: Disseminated vaccinia in a military recruit with human immunode efficiency virus (HIV) disease. N Engl J Med 1987, 316:673–676.PubMedCrossRefGoogle Scholar
  15. 15.
    Kengsakul K, Sathirapongsasuti K, Punyagupta S: Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. J Med Assoc Thai 2002, 85:131–134. First reported case of fatal encephalitis due to YF vaccine in a patient with unrecognized AIDS.PubMedGoogle Scholar
  16. 16.
    Angel JB, Walpita P, Lerch RA, et al.: Vaccine-associated measles pneumonitis in an adult with AIDS. Ann Intern Med 1998, 129:104–106.PubMedGoogle Scholar
  17. 17.
    Goon P, Cohen B, Jin L, et al.: MMR vaccine in HIVinfected children—potential hazards? Vaccine 2001, 19:3816–3819.PubMedCrossRefGoogle Scholar
  18. 18.
    Kramer JM, LaRussa P, Tsai WC, et al.: Disseminated vaccine strain varicella as the acquired immunoDeficiency syndrome-defining illness in a previously undiagnosed child. Pediatrics 2001, 108:E39.PubMedCrossRefGoogle Scholar
  19. 19.
    Ryder RW, Oxtoby MJ, Mvula M, et al.: Safety and immunogenicity of bacille Calmette-Guerin, diphtheriatetanuspertussis, and oral polio vaccines in newborn children in Zaire infected with human immunodeficiency virus type 1. J Pediatr 1993, 122:697–702.PubMedCrossRefGoogle Scholar
  20. 20.
    Wallace MR, Hooper DG, Graves SJ, Malone JL: Measles seroprevalence and vaccine response in HIV-infected adults. Vaccine 1994, 12:1222–1224.PubMedCrossRefGoogle Scholar
  21. 21.
    2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunoDeficiency virus. HIV Clin Trials 2001, 2:493–554. Updated guidelines. A necessary reference for all who provide care for patients with HIV infection.Google Scholar
  22. 22.
    |Centers for Disease Control and Prevention: Health Information for International Travel 2005–2006. Atlanta, GA: US Department of Health and Human Services; 2005. New edition of the CDC’s “yellow book.” Has an excellent section on travelers with HIV infection, as well as a thorough discussion of specific recommendations for each vaccine.Google Scholar
  23. 23.
    Stanley SK, Ostrowski MA, Justement JS, et al.: Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med 1996, 334:1222–1230.PubMedCrossRefGoogle Scholar
  24. 24.
    Wallace MR, Hill HE, Tasker SA, Miller LK: Hepatitis A in human immunoDeficiency virus-infected patients. Clin Infect Dis 1998, 27:651–653.PubMedGoogle Scholar
  25. 25.
    Tasker SA, O’Brien WA, Treanor JJ, et al.: Effects of influenza vaccination in HIV-infected adults: a double-blind, placebo-controlled trial. Vaccine 1998, 16:1039–1042.PubMedCrossRefGoogle Scholar
  26. 26.
    Staprans SI, Hamilton BL, Follansbee SE, et al.: Activation of virus replication after vaccination of HIV-1-infected individuals. J Exp Med 1995, 182:1727–1737.PubMedCrossRefGoogle Scholar
  27. 27.
    Brichacek B, Swindells S, Janoff EN, et al.: Increased plasma human immunoDeficiency virus type 1 burden following antigenic challenge with pneumococcal vaccine. J Infect Dis 1996, 174:1191–1199.PubMedGoogle Scholar
  28. 28.
    Glesby MJ, Hoover DR, Farzadegan H, et al.: The effect of influenza vaccination on human immunoDeficiency virus type 1 load: a randomized, double-blind, placebo-controlled study. J Infect Dis 1996, 174:1332–1336.PubMedGoogle Scholar
  29. 29.
    Tasker SA, Treanor JJ, Paxton WB, Wallace MR: Efficacy of influenza vaccination in HIV-infected persons. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999, 131:430–433.PubMedGoogle Scholar
  30. 30.
    Fuller JD, Craven DE, Steger KA, et al.: Influenza vaccination of human immunoDeficiency virus (HIV)-infected adults: impact on plasma levels of HIV type 1 RNA and determinants of antibody response. Clin Infect Dis 1999, 28:541–547.PubMedGoogle Scholar
  31. 31.
    Fowke KR, D’Amico R, Chernoff DN, et al.: Immunologic and virologic evaluation after influenza vaccination of HIV-1-infected patients. AIDS 1997, 11:1013–1021.PubMedCrossRefGoogle Scholar
  32. 32.
    Ostrowski MA, Stanley SK, Justement JS, et al.: Increased in vitro tetanus-induced production of HIV type 1 following in vivo immunization of HIV type 1-infected individuals with tetanus toxoid. AIDS Res Hum Retroviruses 1997, 13:473–480.PubMedCrossRefGoogle Scholar
  33. 33.
    Weissman D, Barker TD, Fauci AS: The efficiency of acute infection of CD4+ T cells is markedly enhanced in the setting of antigen-specific immune activation. J Exp Med 1996, 183:687–692.PubMedCrossRefGoogle Scholar
  34. 34.
    Farber CM, Barath AA, Dieye T: The effects of immunization in human immunoDeficiency virus type 1 infection. N Engl J Med 1996, 335:817–819.PubMedCrossRefGoogle Scholar
  35. 35.
    Talesnik E, Vial PA, Labarca J, et al.: Time course of antibody response to tetanus toxoid and pneumococcal capsular polysaccharides in patients infected with HIV. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 19:471–477.PubMedGoogle Scholar
  36. 36.
    French N, Nakiyingi J, Carpenter LM, et al.: 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet 2000, 355:2106–2111. Only study to date which has demonstrated potential harm of pneumococcal vaccine in patients with HIV infection, paradoxically finding an increase in invasive pneumococcal disease in vaccine recipients.PubMedCrossRefGoogle Scholar
  37. 37.
    Recommendations of the Advisory Committee on Immunization Practices (ACIP): use of vaccines and immune globulins for persons with altered immunocompetence. MMWR Recomm Rep 1993, 42:1–18.Google Scholar
  38. 38.
    Rosenblatt HM, Song LY, Nachman SA, et al.: Tetanus immunity after diphtheria, tetanus toxoids, and acellular pertussis vaccination in children with clinically stable HIV infection. J Allergy Clin Immunol 2005, 116:698–703.PubMedCrossRefGoogle Scholar
  39. 39.
    Bonetti TC, Succi RC, Weckx LY, et al.: Tetanus and diphtheria antibodies and response to a booster dose in Brazilian HIV-1-infected women. Vaccine 2004, 22:3707–3712.PubMedCrossRefGoogle Scholar
  40. 40.
    Jackson LA, Cherry JD, Wang SP, Grayston JT: Frequency of serological evidence of Bordetella infections and mixed infections with other respiratory pathogens in university students with cough illnesses. Clin Infect Dis 2000, 31:3–6.PubMedCrossRefGoogle Scholar
  41. 41.
    Cohn SE, Knorr KL, Gilligan PH, et al.: Pertussis is rare in human immunoDeficiency virus disease. Am Rev Respir Dis 1993, 147:411–413.PubMedGoogle Scholar
  42. 42.
    de Martino M, Podda A, Galli L, et al.: Acellular pertussis vaccine in children with perinatal human immunode-deficiency virus-type 1 infection. Vaccine 1997, 15:1235–1238.PubMedCrossRefGoogle Scholar
  43. 43.
    Pichichero ME, Rennels MB, Edwards KM, et al.: Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults. JAMA 2005, 293:3003–3011.PubMedCrossRefGoogle Scholar
  44. 44.
    Read JS, Frasch CE, Rich K, et al.: The immunogenicity of Haemophilus influenzae type b conjugate vaccines in children born to human immunoDeficiency virusinfected women. Women and Infants Transmission Study Group. Pediatr Infect Dis J 1998, 17:391–397.PubMedCrossRefGoogle Scholar
  45. 45.
    Madhi SA, Petersen K, Khoosal M, et al.: Reduced effectiveness of Haemophilus influenzae type b conjugate vaccine in children with a high prevalence of human immunode ficiency virus type 1 infection. Pediatr Infect Dis J 2002, 21:315–321.PubMedCrossRefGoogle Scholar
  46. 46.
    Madhi SA, Kuwanda L, Saarinen L, et al.: Immunogenicity and effectiveness of Haemophilus influenzae type b conjugate vaccine in HIV infected and uninfected African children. Vaccine 2005, 23:5517–5525. This study demonstrated that although quantitative antibody responses may be similar between HIV-infected and non-HIVinfected patients, functional antibody may be decreased.PubMedCrossRefGoogle Scholar
  47. 47.
    Steinhart R, Reingold AL, Taylor F, et al.: Invasive Haemophilus influenzae infections in men with HIV infection. JAMA 1992, 268:3350–3352.PubMedCrossRefGoogle Scholar
  48. 48.
    Phares C, Hanson D, Flannery B, et al.: Invasive pneumococcal disease in HIV-infected adults: Impact of pneumococcal vaccination and highly active antiretroviral therapy (HAART) [abstract 864]. Paper presented at the Annual Meeting of the Infectious Diseases Society of America. San Francisco, CA; October 6–9, 2005.Google Scholar
  49. 49.
    Grau I, Pallares R, Tubau F, et al.: Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunoDeficiency virus in the era of highly active antiretroviral therapy. Arch Intern Med 2005, 165:1533–1540.PubMedCrossRefGoogle Scholar
  50. 50.
    Frankel RE, Virata M, Hardalo C, et al.: Invasive pneumococcal disease: clinical features, serotypes, and antimicrobial resistance patterns in cases involving patients with and without human immunoDeficiency virus infection. Clin Infect Dis 1996, 23:577–584.PubMedGoogle Scholar
  51. 51.
    Feikin DR, Elie CM, Goetz MB, et al.: Specificity of the antibody response to the pneumococcal polysaccharide and conjugate vaccines in human immunoDeficiency virus-infected adults. Clin Diagn Lab Immunol 2004, 11:137–141.PubMedCrossRefGoogle Scholar
  52. 52.
    Nielsen H, Kvinesdal B, Benfield TL, et al.: Rapid loss of specific antibodies after pneumococcal vaccination in patients with human immunoDeficiency virus-1 infection. Scand J Infect Dis 1998, 30:597–601.PubMedCrossRefGoogle Scholar
  53. 53.
    Arpadi SM, Back S, O’Brien J, Janoff EN: Antibodies to pneumococcal capsular polysaccharides in children with human immunoDeficiency virus infection given polyvalent pneumococcal vaccine. J Pediatr 1994, 125:77–79.PubMedCrossRefGoogle Scholar
  54. 54.
    Tasker SA, Wallace MR, Rubins JB, et al.: Reimmunization with 23-valent pneumococcal vaccine for patients infected with human immunoDeficiency virus type 1: clinical, immunologic, and virologic responses. Clin Infect Dis 2002, 34:813–821.PubMedCrossRefGoogle Scholar
  55. 55.
    Gebo KA, Moore RD, Keruly JC, Chaisson RE: Risk factors for pneumococcal disease in human immunoDeficiency virus-infected patients. J Infect Dis 1996, 173:857–862.PubMedGoogle Scholar
  56. 56.
    Guerrero M, Kruger S, Saitoh A, et al.: Pneumonia in HIVinfected patients: a case-control survey of factors involved in risk and prevention. AIDS 1999, 13:1971–1975.PubMedCrossRefGoogle Scholar
  57. 57.
    Lopez-Palomo C, Martin-Zamorano M, Benitez E, et al.: Pneumonia in HIV-infected patients in the HAART era: incidence, risk, and impact of the pneumococcal vaccination. J Med Virol 2004, 72:517–524.PubMedCrossRefGoogle Scholar
  58. 58.
    Teshale E, Hanson D, Flannery B, et al.: Effect of 23-valent pneumococcal polysaccharide vaccine on the incidence of all cause pneumonia in the highly active antiretroviral therapy (HAART) era [abstract 863]. Paper presented at the Annual Meeting of the Infectious Diseases Society of America. San Francisco, CA; October 6–9, 2005.Google Scholar
  59. 59.
    French N, Moore M, Haikala R, et al.: A case-control study to investigate serological correlates of clinical failure of 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults. J Infect Dis 2004, 190:707–712.PubMedCrossRefGoogle Scholar
  60. 60.
    Black S, Shinefield H, Fireman B, et al.: Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000, 19:187–195.PubMedCrossRefGoogle Scholar
  61. 61.
    King JC Jr, Vink PE, Farley JJ, et al.: Safety and immunogenicity of three doses of a five-valent pneumococcal conjugate vaccine in children younger than two years with and without human immunoDeficiency virus infection. Pediatrics 1997, 99:575–580.PubMedCrossRefGoogle Scholar
  62. 62.
    Klugman KP, Madhi SA, Huebner RE, et al.: A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003, 349:1341–1348.PubMedCrossRefGoogle Scholar
  63. 63.
    Madhi SA, Kuwanda L, Cutland C, et al.: Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunoDeficiency virus-infected and uninfected children. Pediatr Infect Dis J 2005, 24:410–416.PubMedCrossRefGoogle Scholar
  64. 64.
    Kroon FP, van Dissel JT, Ravensbergen E, et al.: Impaired antibody response after immunization of HIV-infected individuals with the polysaccharide vaccine against Salmonella typhi (Typhim-Vi). Vaccine 1999, 17:2941–2945.PubMedCrossRefGoogle Scholar
  65. 65.
    Ahmed F, Steinhoff MC, Rodriguez-Barradas MC, et al.: Effect of human immunoDeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: results from a randomized trial. J Infect Dis 1996, 173:83–90.PubMedGoogle Scholar
  66. 66.
    Kroon FP, van Dissel JT, Ravensbergen E, et al.: Enhanced antibody response to pneumococcal polysaccharide vaccine after prior immunization with conjugate pneumococcal vaccine in HIV-infected adults. Vaccine 2000, 19:886–894.PubMedCrossRefGoogle Scholar
  67. 67.
    Bilukha OO, Rosenstein N: Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2005, 54:1–21.PubMedGoogle Scholar
  68. 68.
    Richmond P, Kaczmarski E, Borrow R, et al.: Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine. J Infect Dis 2000, 181:761–764.PubMedCrossRefGoogle Scholar
  69. 69.
    Guillain-Barre syndrome among recipients of Menactra meningococcal conjugate vaccine—United States, June-July 2005. Morb Mortal Wkly Rep Dispatch 2005, 54:1–3.Google Scholar
  70. 70.
    Pile JC, Malone JD, Eitzen EM, Friedlander AM: Anthrax as a potential biological warfare agent. Arch Intern Med 1998, 158:429–434.PubMedCrossRefGoogle Scholar
  71. 71.
    Hesseling AC, Schaaf HS, Hanekom WA, et al.: Danish bacille Calmette-Guerin vaccine-induced disease in human immunoDeficiency virus-infected children. Clin Infect Dis 2003, 37:1226–1233.PubMedCrossRefGoogle Scholar
  72. 72.
    Puthanakit T, Oberdorfer P, Punjaisee S, et al.: Immune reconstitution syndrome due to bacillus Calmette-Guerin after initiation of antiretroviral therapy in children with HIV infection. Clin Infect Dis 2005, 41:1049–1052.PubMedCrossRefGoogle Scholar
  73. 73.
    Krasinski K, Borkowsky W: Measles and measles immunity in children infected with human immunoDeficiency virus. JAMA 1989, 261:2512–2516.PubMedCrossRefGoogle Scholar
  74. 74.
    Arpadi SM, Markowitz LE, Baughman AL, et al.: Measles antibody in vaccinated human immunoDeficiency virus type 1-infected children. Pediatrics 1996, 97:653–657.PubMedGoogle Scholar
  75. 75.
    Berkelhamer S, Borock E, Elsen C, et al.: Effect of highly active antiretroviral therapy on the serological response to additional measles vaccinations in human immunode efficiency virus-infected children. Clin Infect Dis 2001, 32:1090–1094.PubMedCrossRefGoogle Scholar
  76. 76.
    Lima M, De Menezes Succi RC, Nunes Dos Santos AM, et al.: Rubella immunization in human immunoDeficiency virus type 1-infected children: cause for concern in vaccination strategies. Pediatr Infect Dis J 2004, 23:604–607.PubMedCrossRefGoogle Scholar
  77. 77.
    von Seidlein L, Gillette SG, Bryson Y, et al.: Frequent recurrence and persistence of varicella-zoster virus infections in children infected with human immunoDeficiency virus type 1. J Pediatr 1996, 128:52–57.CrossRefGoogle Scholar
  78. 78.
    Wallace MR, Hooper DG, Pyne JM, et al.: Varicella immunity and clinical disease in HIV-infected adults. South Med J 1994, 87:74–76.PubMedGoogle Scholar
  79. 79.
    Levin MJ, Gershon AA, Weinberg A, et al.: Immunization of HIV-infected children with varicella vaccine. J Pediatr 2001, 139:305–310.PubMedCrossRefGoogle Scholar
  80. 80.
    Oxman MN, Levin MJ, Johnson GR, et al.: A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005, 352:2271–2284.PubMedCrossRefGoogle Scholar
  81. 81.
    Gershon AA: Prevention and treatment of VZV infections in patients with HIV. Herpes 2001, 8:32–36.PubMedGoogle Scholar
  82. 82.
    Neuzil KM, Reed GW, Mitchel EF Jr, Griffin MR: Influenza-associated morbidity and mortality in young and middle-aged women. JAMA 1999, 281:901–907.PubMedCrossRefGoogle Scholar
  83. 83.
    Safrin S, Rush JD, Mills J: Influenza in patients with human immunoDeficiency virus infection. Chest 1990, 98:33–37.PubMedGoogle Scholar
  84. 84.
    Evans KD, Kline MW: Prolonged influenza A infection responsive to rimantadine therapy in a human immunode efficiency virus-infected child. Pediatr Infect Dis J 1995, 14:332–334.PubMedCrossRefGoogle Scholar
  85. 85.
    Miotti PG, Nelson KE, Dallabetta GA, et al.: The influence of HIV infection on antibody responses to a two-dose regimen of influenza vaccine. JAMA 1989, 262:779–783.PubMedCrossRefGoogle Scholar
  86. 86.
    Yamanaka H, Teruya K, Tanaka M, et al.: Efficacy and immunologic responses to influenza vaccine in HIV-1-infected patients. J Acquir Immune Defic Syndr 2005, 39:167–173.PubMedGoogle Scholar
  87. 87.
    King JC Jr, Fast PE, Zangwill KM, et al.: Safety, vaccine virus shedding and immunogenicity of trivalent, coldadapted, live attenuated influenza vaccine administered to human immunoDeficiency virus-infected and noninfected children. Pediatr Infect Dis J 2001, 20:1124–1131.PubMedCrossRefGoogle Scholar
  88. 88.
    King JC Jr, Treanor J, Fast PE, et al.: Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunoDeficiency virus (HIV)-infected and non-HIV-infected adults. J Infect Dis 2000, 181:725–728.PubMedCrossRefGoogle Scholar
  89. 89.
    Wallace MR, Brandt CJ, Earhart KC, et al.: Safety and immunogenicity of an inactivated hepatitis A vaccine among HIV-infected subjects. Clin Infect Dis 2004, 39:1207–1213.PubMedCrossRefGoogle Scholar
  90. 90.
    Kemper CA, Haubrich R, Frank I, et al.: Safety and immunogenicity of hepatitis A vaccine in human immunoDeficiency virus-infected patients: a double-blind, randomized, placebo-controlled trial. J Infect Dis 2003, 187:1327–1331.PubMedCrossRefGoogle Scholar
  91. 91.
    Gouvea AF, De Moraes-Pinto MI, Ono E, et al.: Immunogenicity and tolerability of hepatitis A vaccine in HIV-infected children. Clin Infect Dis 2005, 41:544–548.PubMedCrossRefGoogle Scholar
  92. 92.
    Gandhi RT, Wurcel A, Lee H, et al.: Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies. J Infect Dis 2005, 191:1435–1441. This group demonstrated similar anamnestic responses to hepatitis B vaccine in HIV-infected patients with and without an isolated antibody to anti-HBc, suggesting a need to reevaluate the use of this antibody as a criterion for exclusion from vaccination.PubMedCrossRefGoogle Scholar
  93. 93.
    Fonseca MO, Pang LW, de Paula Cavalheiro N, et al.: Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine 2005, 23:2902–2908.PubMedCrossRefGoogle Scholar
  94. 94.
    Amorosa VK, Isaacs SN: Separate worlds set to collide: smallpox, vaccinia virus vaccination, and human immunoDeficiency virus and acquired immunoDeficiency syndrome. Clin Infect Dis 2003, 37:426–432.PubMedCrossRefGoogle Scholar
  95. 95.
    Tasker SA, Schnepf GA, Lim M, et al.: Unintended smallpox vaccination of HIV-1-infected individuals in the United States military. Clin Infect Dis 2004, 38:1320–1322.PubMedCrossRefGoogle Scholar
  96. 96.
    Sibailly TS, Wiktor SZ, Tsai TF, et al.: Poor antibody response to yellow fever vaccination in children infected with human immunoDeficiency virus type 1. Pediatr Infect Dis J 1997, 16:1177–1179.PubMedCrossRefGoogle Scholar
  97. 97.
    Tattevin P, Depatureaux AG, Chapplain JM, et al.: Yellow fever vaccine is safe and effective in HIV-infected patients. Aids 2004, 18:825–827.PubMedCrossRefGoogle Scholar
  98. 98.
    Rojanasuphot S, Shaffer N, Chotpitayasunondh T, et al.: Response to JE vaccine among HIV-infected children, Bangkok, Thailand. Southeast Asian J Trop Med Public Health 1998, 29:443–450.PubMedGoogle Scholar
  99. 99.
    Panasiuk B, Prokopowicz D, Panasiuk A: Immunological response in HIV-positive patients vaccinated against tick-borne encephalitis. Infection 2003, 31:45–46.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2006

Authors and Affiliations

  • Todd D. Gleeson
  • Mark R. Wallace
  • Sybil A. Tasker
    • 1
  1. 1.Department of Infectious DiseasesNational Naval Medical CenterBethesdaUSA

Personalised recommendations